Pages Navigation Menu

Speed on the Gulf

Xarelto Alternatives and Competitors

Blood thinners are a common form of treatment for patients after surgery or those at risk of stroke. While blood thinners are considered to be a dangerous subgroup of drugs, there were never severe or frequent cases of adverse side effects from one specific drug. The market leaders, Warfarin and Coumadin, reported few patients with serious side effects due to the drug.

Warfarin and Coumadin required two pills daily, substantial dietary restrictions, and frequent doctor visits to monitor the amount of drug in the blood. The dose of two pills per day maintained a consistent level of the drug within the body over the course of the day to prevent bleeding episodes.

In 2011, Johnson & Johnson and Bayer released Xarelto as an alternative to the hassle of taking Warfarin and Coumadin. It was marketed to individuals that did not want the doctor visits and blood testing associated with the previous medical options. The drug manufacturers claimed the blood testing was not a necessary step to preventing bleeding episodes.

Reportedly, a number of Xarelto patients suffered from preventable bleeding episodes due to the oversight of the drug manufacturer. There were problems associated with dosage that frequent doctor visits and blood tests would have caught. Some of the more serious preventable bleeding incidents resulted in severe injury or death of the patient. According to the website of the lawyers at the Williams Kherkher law firm, one of the fatal types of bleeding that Xarelto can cause is severe gastrointestinal bleeding.

Also unlike its competitors, Xarelto does not have a reversal agent. An antidote would normally be used to stop the bleeding episode before it became deadly. Without one, Xarelto patients must endure the bleeding incident until the drug is out of the blood system. This could take several hours or days to completely occur, leaving the patient helpless during this time. Xarelto is currently under scrutiny by the FDA.

Leave a Comment

Your email address will not be published. Required fields are marked *